Tandem Diabetes Care, Insulet and Dexcom all presented data over the weekend at the American Diabetes Association’s Scientific Sessions.

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc.

Insulet Corporation (PODD) and DexCom (DXCM) were among notable gainers in MedTech on Tuesday after Deutsche Bank initiated the diabetes device makers with Buy ratings despite their sharp sell-off in ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has ...

Tandem Diabetes has gotten torched over the last six months - since December 2025, its stock price has dropped 25.8% to ...

Tandem Diabetes narrowed fiscal 2025 sales guidance from $997 million-$1.01 billion to $1 billion compared to the consensus of $1.004 billion. “Our narrowed guidance reflects insights gained in the ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial markets close on Thursday, ...

Ali Dianaty, MiniMed’s chief product and technology officer, believes the company is “clearly ahead” of the competition in ...

Tandem Diabetes Care's top-line growth hasn't been great over the past few years. If it can successfully address challenges detrimental to revenue growth, it may become an attractive stock -- even ...

Tandem Diabetes Care, Inc. (TNDM Quick Quote TNDM - Free Report) is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. Its strong ...